<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848041</url>
  </required_header>
  <id_info>
    <org_study_id>RVL-1201-001</org_study_id>
    <nct_id>NCT01848041</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis</brief_title>
  <official_title>A Randomized, Double-Masked, Placebo-Controlled Phase 1/2a Study of the Efficacy and Safety of Two Dosing Regimens of RVL-1201 in the Treatment of Acquired Blepharoptosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RVL Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RVL Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, proof of concept study to evaluate the safety and efficacy of&#xD;
      RVL-1201 dosed once or twice daily for 14 days compared to a placebo (vehicle) control in&#xD;
      patients with ptosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an exploratory, proof-of-concept study. The objectives include establishing the&#xD;
      efficacy and duration of effect of once daily (QD) or twice daily (BID) administration of&#xD;
      RVL-1201 and the safety profile following 14 days of treatment in 72 subjects (24 per arm)&#xD;
      with acquired blepharoptosis.&#xD;
&#xD;
      Efficacy will be assessed at each treatment visit by the Humphrey Visual Field 36-point&#xD;
      ptosis protocol test, photographic measurement of marginal reflex distance, palpebral fissure&#xD;
      distance and contrast sensitivity in the study eye only and Visual Acuity assessment in both&#xD;
      eyes.&#xD;
&#xD;
      Safety assessments will include slit lamp examination/corneal fluorescein staining, pupil&#xD;
      size measurement, ophthalmoscopy/ fundus examination, tonometry, visual acuity; urine&#xD;
      pregnancy test (for women of childbearing potential only), vital signs (Heart Rate/Blood&#xD;
      Pressure); and collection of adverse events. Subject rating of study medication comfort and&#xD;
      assessment of ongoing tolerability will also be obtained.&#xD;
&#xD;
      Primary efficacy endpoint is the mean increase from baseline in points seen on the HVF&#xD;
      36-point ptosis protocol test at various timepoints according to a hierarchical analysis.&#xD;
&#xD;
      Analysis of exploratory endpoints will provide characterization of the efficacy and duration&#xD;
      of effect of RVL-1201 with a variety of efficacy measures, as well as the potential&#xD;
      additional effect of BID over QD dosing and safety profile of BID administration of RVL-1201.&#xD;
      Exploratory endpoints will be analyzed by each regimen against placebo and between regimens&#xD;
      and will include:&#xD;
&#xD;
        -  The change from baseline in HVF, MRD, PFD, VA, and CS.&#xD;
&#xD;
        -  The change from baseline in BP/HR&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Humphrey Visual Field</measure>
    <time_frame>Baseline (Day 0, Hour 0), Visit 4 (Day 13, Hour 2) and Visit 4 (Day 13, Hour 6)</time_frame>
    <description>The mean change from baseline (Day 0, Hour 0) in number of points seen on the HVF 36-point ptosis protocol test according to a pre-planned hierarchical analysis as follows:&#xD;
Hour 6 on Visit 4 (Day 13) for the BID regimen versus vehicle&#xD;
Hour 6 on Visit 4 (Day 13) for the QD regimen versus vehicle&#xD;
Hour 2 on Visit 4 (Day 13) for the BID regimen versus vehicle&#xD;
Hour 2 on Visit 4 (Day 13) for the QD regimen versus vehicle&#xD;
Testing was performed using a Humphrey perimeter at a grid of 36 points confined to the superior hemifield extending 55° to either side of fixation and 45° superior to fixation. Testing was accomplished in the standard fashion using a varying 4-mm2 or 5-mm2 stimulus to determine the visual sensitivity for each grid point in the field (Riemann et al, 2000). A 4-mm2 stimulus was acceptable, but a 5-mm2 stimulus was preferred, if available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Marginal Reflex Distance</measure>
    <time_frame>Baseline (Day 0, Hour 0), Visit 4 (Day 13, Hour 2) and Visit 4 (Day 13, Hour 6)</time_frame>
    <description>Change from baseline in MRD by regimen against placebo and between regimen.&#xD;
The distance from the pupillary light reflex to the central margin of the upper eyelid is the MRD. The MRD will be measured from the external photograph using calipers and the millimeter ruler as the legend.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palpebral Fissure Distance Measurement</measure>
    <time_frame>Baseline (Day 0, Hour 0), Visit 4 (Day 13, Hour 2) and Visit 4 (Day 13, Hour 6)</time_frame>
    <description>Change from baseline in PFD by regimen against placebo and between regimen.&#xD;
The PFD is the distance from the upper lid margin to the lower lid margin measured through the central visual axis. It will be measured from the external photograph using handheld calipers and the millimeter ruler as the legend.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>Baseline (Day 0, Hour 0), Visit 4 (Day 13, Hour 2) and Visit 4 (Day 13, Hour 6)</time_frame>
    <description>Change from baseline in CS by regimen against placebo and between regimen.&#xD;
The Pelli-Robson contrast sensitivity chart will be used at a distance of 1 meter. The subject was instructed to begin reading the letters at the top of the chart and to continue reading across and down the chart. Testing was discontinued when 2 of 3 letters were named incorrectly. The test was scored using the letter-by-letter method where a value of 0.05 log CS is given per correct letter (Haymes et al, 2006).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected Snellen Visual Acuity</measure>
    <time_frame>Baseline (Day 0, Hour 0), Visit 4 (Day 13, Hour 2) and Visit 4 (Day 13, Hour 6)</time_frame>
    <description>Change from baseline in VA by regimen against placebo and between regimen.&#xD;
Corrected Snellen VA measurement was performed with the Snellen eye chart using subjects current corrective lens prescription at a distance equivalent to 20 feet (6 meters).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Blepharoptosis</condition>
  <arm_group>
    <arm_group_label>RVL-1201 once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RVL-1201 twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RVL-1201 vehicle (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVL-1201</intervention_name>
    <description>RVL-1201 0.1% Ophthalmic Solution</description>
    <arm_group_label>RVL-1201 once daily</arm_group_label>
    <arm_group_label>RVL-1201 twice daily</arm_group_label>
    <other_name>Oxymetazoline Hydrochloride Ophthalmic Solution 0.1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVL-1201 Vehicle Placebo</intervention_name>
    <description>RVL-1201 Vehicle Placebo</description>
    <arm_group_label>RVL-1201 vehicle (placebo)</arm_group_label>
    <other_name>RVL-1201 Ophthalmic Solution 0.1% Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult male or female subjects 18 years of age and older.&#xD;
&#xD;
          2. Presence of all of the following at Screening:&#xD;
&#xD;
               1. Loss on HVF 36-point ptosis protocol test of ≥ 8 points in points not seen at or&#xD;
                  above 10° from fixation in the superior visual field; AND&#xD;
&#xD;
               2. Marginal reflex distance (MRD), the distance from the central pupillary light&#xD;
                  reflex to the upper lid margin, of ≤ 2.5 mm in the same eye as Inclusion&#xD;
                  Criterion #2a; AND&#xD;
&#xD;
               3. Corrected Snellen visual acuity (VA) of 20/40 or better (refraction must be&#xD;
                  within 6 months of Visit 1) in the same eye as Inclusion Criteria #2a and #2b.&#xD;
&#xD;
          3. No contraindications for treatment of both eyes as specified in Exclusion Criteria&#xD;
             #1-14.&#xD;
&#xD;
          4. Female subjects must be 1-year postmenopausal, surgically sterilized, or women of&#xD;
             childbearing potential with a negative urine pregnancy test at Visit 1. Women of&#xD;
             childbearing potential must use an acceptable form of contraception throughout the&#xD;
             study.&#xD;
&#xD;
          5. Provide informed consent prior to undergoing any study-related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        In either eye:&#xD;
&#xD;
          1. Congenital ptosis&#xD;
&#xD;
          2. Pseudoptosis&#xD;
&#xD;
          3. Horner syndrome&#xD;
&#xD;
          4. Marcus Gunn jaw-winking syndrome&#xD;
&#xD;
          5. Myasthenia gravis&#xD;
&#xD;
          6. Mechanical ptosis, including ptosis due to orbital or lid tumor, cicatricial processes&#xD;
             affecting the movements of the upper lid, and enophthalmos&#xD;
&#xD;
          7. Dermatochalasis as the sole cause of the signs of ptosis&#xD;
&#xD;
          8. Previous ptosis surgery&#xD;
&#xD;
          9. Lid position affected by lid or conjunctival scarring&#xD;
&#xD;
         10. Current use of prescribed dry eye medication or punctal plugs; artificial tears are&#xD;
             allowed&#xD;
&#xD;
         11. Visual field loss from any cause other than ptosis&#xD;
&#xD;
         12. Inability to fixate on the central fixation target of the HVF&#xD;
&#xD;
         13. Primary open-angle glaucoma or ocular hypertension, intraocular pressure (IOP) &gt; 24 mm&#xD;
             Hg, or current use/use within 1 month prior to Visit 1 of any antiglaucoma&#xD;
             medications.&#xD;
&#xD;
         14. History of closed/narrow angle glaucoma (unless patent peripheral iridotomy has been&#xD;
             performed &gt; 3 months prior to Visit 1 and IOP &lt; 20 mm Hg) or normal-tension glaucoma&#xD;
&#xD;
         15. Use of over-the-counter vasoconstrictor/decongestant eye medication (eg, Visine®&#xD;
             L.R.®) or any α-adrenergic agonist (including OTC products) at any time during the&#xD;
             study&#xD;
&#xD;
         16. Contact lens wear during the study period&#xD;
&#xD;
             General:&#xD;
&#xD;
         17. Resting heart rate (HR) outside the normal range (60 - 100 beats per minute)&#xD;
&#xD;
         18. Hypertension diastolic blood pressure (BP) &gt; 105 mm Hg&#xD;
&#xD;
         19. Use of monoamine oxidase inhibitors (MAOIs; eg, isocarboxazid, phenelzine,&#xD;
             tranylcypromine) within 14 days prior to Visit 1 or during the study&#xD;
&#xD;
         20. Use of beta blockers (eg, propranolol, metoprolol, labetalol) within 14 days prior to&#xD;
             Visit 1 or during the study&#xD;
&#xD;
         21. Use of maprotiline, selective serotonin reuptake inhibitors ([SSRIs] eg, citalopram,&#xD;
             escitalopram, paroxetine, fluoxetine, fluvoxamine, sertraline) or tricyclic&#xD;
             antidepressants (eg, amitriptyline, doxepin, nortriptyline, amoxapine, clomipramine,&#xD;
             desipramine, imipramine, protriptyline, trimipramine) at any time during the study&#xD;
&#xD;
         22. A history of myocardial infarction, angina, arrhythmia, or irregular pulse&#xD;
&#xD;
         23. Advanced arteriosclerotic disease&#xD;
&#xD;
         24. History of thyroid disease&#xD;
&#xD;
         25. Insulin-dependent diabetes or diabetes requiring oral hypoglycemic drugs;&#xD;
             diet-controlled diabetes is allowed&#xD;
&#xD;
         26. Pregnancy or lactation&#xD;
&#xD;
         27. Diagnosed benign prostatic hypertrophy requiring medicinal therapy.&#xD;
&#xD;
         28. History of contact or systemic allergic reaction to oxymetazoline or other&#xD;
             sympathomimetic drugs (eg, phenylephrine, pseudoephedrine, ephedrine,&#xD;
             phenylpropanolamine, fepradinol, or methoxamine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuck Slonim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oculos Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 3, 2013</study_first_submitted>
  <study_first_submitted_qc>May 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <results_first_submitted>July 1, 2021</results_first_submitted>
  <results_first_submitted_qc>July 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2021</results_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blepharoptosis</keyword>
  <keyword>Ptosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharoptosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RVL-1201 QD</title>
          <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
        </group>
        <group group_id="P2">
          <title>RVL-1201 BID</title>
          <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
        </group>
        <group group_id="P3">
          <title>RVL-1201 Vehicle (Placebo) BID</title>
          <description>RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201 Vehicle Placebo: RVL-1201 Vehicle Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat (ITT) Population</population>
      <group_list>
        <group group_id="B1">
          <title>RVL-1201 QD</title>
          <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
        </group>
        <group group_id="B2">
          <title>RVL-1201 BID</title>
          <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
        </group>
        <group group_id="B3">
          <title>RVL-1201 Vehicle (Placebo) BID</title>
          <description>RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201 Vehicle Placebo: RVL-1201 Vehicle Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="10.33"/>
                    <measurement group_id="B2" value="58.7" spread="10.47"/>
                    <measurement group_id="B3" value="58.3" spread="11.23"/>
                    <measurement group_id="B4" value="60.4" spread="10.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="40" upper_limit="78"/>
                    <measurement group_id="B2" value="60" lower_limit="34" upper_limit="75"/>
                    <measurement group_id="B3" value="60" lower_limit="33" upper_limit="73"/>
                    <measurement group_id="B4" value="61.5" lower_limit="33" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Iris Color OD/OS</title>
          <description>Right Eye (OD), Left Eye (OS)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Iris Color OD</title>
              <category_list>
                <category>
                  <title>Blue</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Brown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Green</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hazel</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grey</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iris Color OS</title>
              <category_list>
                <category>
                  <title>Blue</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Brown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Green</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hazel</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grey</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lens Status OD/OS</title>
          <description>Lens Status of Phakic (implanted together with the natural), Aphakic (missing) or Pseudophakic (false - meaning not natural) is the type of eye lens. Right Eye (OD), Left Eye (OS)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lens Status OD</title>
              <category_list>
                <category>
                  <title>Phakic, a person with an intact natural lens</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Aphakic, a person with a natural lens was extracted and no intraocular lens was implanted.</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pseudophakic, a person who has had a lens extracted and an intraocular lens placed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lens Status OS</title>
              <category_list>
                <category>
                  <title>Phakic, a person with an intact natural lens</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Aphakic, a person with a natural lens was extracted and no intraocular lens was implanted.</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pseudophakic, a person who has had a lens extracted and an intraocular lens placed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Humphrey Visual Field</title>
        <description>The mean change from baseline (Day 0, Hour 0) in number of points seen on the HVF 36-point ptosis protocol test according to a pre-planned hierarchical analysis as follows:&#xD;
Hour 6 on Visit 4 (Day 13) for the BID regimen versus vehicle&#xD;
Hour 6 on Visit 4 (Day 13) for the QD regimen versus vehicle&#xD;
Hour 2 on Visit 4 (Day 13) for the BID regimen versus vehicle&#xD;
Hour 2 on Visit 4 (Day 13) for the QD regimen versus vehicle&#xD;
Testing was performed using a Humphrey perimeter at a grid of 36 points confined to the superior hemifield extending 55° to either side of fixation and 45° superior to fixation. Testing was accomplished in the standard fashion using a varying 4-mm2 or 5-mm2 stimulus to determine the visual sensitivity for each grid point in the field (Riemann et al, 2000). A 4-mm2 stimulus was acceptable, but a 5-mm2 stimulus was preferred, if available.</description>
        <time_frame>Baseline (Day 0, Hour 0), Visit 4 (Day 13, Hour 2) and Visit 4 (Day 13, Hour 6)</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>RVL-1201 Once Daily</title>
            <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
          </group>
          <group group_id="O2">
            <title>RVL-1201 Twice Daily</title>
            <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
          </group>
          <group group_id="O3">
            <title>RVL-1201 Vehicle (Placebo)</title>
            <description>RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201 Vehicle Placebo: RVL-1201 Vehicle Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Humphrey Visual Field</title>
          <description>The mean change from baseline (Day 0, Hour 0) in number of points seen on the HVF 36-point ptosis protocol test according to a pre-planned hierarchical analysis as follows:&#xD;
Hour 6 on Visit 4 (Day 13) for the BID regimen versus vehicle&#xD;
Hour 6 on Visit 4 (Day 13) for the QD regimen versus vehicle&#xD;
Hour 2 on Visit 4 (Day 13) for the BID regimen versus vehicle&#xD;
Hour 2 on Visit 4 (Day 13) for the QD regimen versus vehicle&#xD;
Testing was performed using a Humphrey perimeter at a grid of 36 points confined to the superior hemifield extending 55° to either side of fixation and 45° superior to fixation. Testing was accomplished in the standard fashion using a varying 4-mm2 or 5-mm2 stimulus to determine the visual sensitivity for each grid point in the field (Riemann et al, 2000). A 4-mm2 stimulus was acceptable, but a 5-mm2 stimulus was preferred, if available.</description>
          <population>Intent to Treat Population</population>
          <units>Points seen</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Base Line (Day 0, Hour 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="5.07"/>
                    <measurement group_id="O2" value="12.1" spread="4.64"/>
                    <measurement group_id="O3" value="11.1" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 13, Hour 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="5.35"/>
                    <measurement group_id="O2" value="15.7" spread="4.63"/>
                    <measurement group_id="O3" value="15.7" spread="5.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 13, Hour 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="5.29"/>
                    <measurement group_id="O2" value="17.0" spread="4.51"/>
                    <measurement group_id="O3" value="17.1" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Marginal Reflex Distance</title>
        <description>Change from baseline in MRD by regimen against placebo and between regimen.&#xD;
The distance from the pupillary light reflex to the central margin of the upper eyelid is the MRD. The MRD will be measured from the external photograph using calipers and the millimeter ruler as the legend.</description>
        <time_frame>Baseline (Day 0, Hour 0), Visit 4 (Day 13, Hour 2) and Visit 4 (Day 13, Hour 6)</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>RVL-1201 Once Daily</title>
            <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
          </group>
          <group group_id="O2">
            <title>RVL-1201 Twice Daily</title>
            <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
          </group>
          <group group_id="O3">
            <title>RVL-1201 Vehicle (Placebo)</title>
            <description>RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201 Vehicle Placebo: RVL-1201 Vehicle Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Marginal Reflex Distance</title>
          <description>Change from baseline in MRD by regimen against placebo and between regimen.&#xD;
The distance from the pupillary light reflex to the central margin of the upper eyelid is the MRD. The MRD will be measured from the external photograph using calipers and the millimeter ruler as the legend.</description>
          <population>Intent to Treat Population</population>
          <units>Millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0, Hour 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.77"/>
                    <measurement group_id="O2" value="1.6" spread="0.84"/>
                    <measurement group_id="O3" value="1.6" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 13, Hour 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.99"/>
                    <measurement group_id="O2" value="2.3" spread="1.19"/>
                    <measurement group_id="O3" value="2.0" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 13, Hour 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.00"/>
                    <measurement group_id="O2" value="2.5" spread="1.13"/>
                    <measurement group_id="O3" value="2.2" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Palpebral Fissure Distance Measurement</title>
        <description>Change from baseline in PFD by regimen against placebo and between regimen.&#xD;
The PFD is the distance from the upper lid margin to the lower lid margin measured through the central visual axis. It will be measured from the external photograph using handheld calipers and the millimeter ruler as the legend.</description>
        <time_frame>Baseline (Day 0, Hour 0), Visit 4 (Day 13, Hour 2) and Visit 4 (Day 13, Hour 6)</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>RVL-1201 Once Daily</title>
            <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
          </group>
          <group group_id="O2">
            <title>RVL-1201 Twice Daily</title>
            <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
          </group>
          <group group_id="O3">
            <title>RVL-1201 Vehicle (Placebo)</title>
            <description>RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201 Vehicle Placebo: RVL-1201 Vehicle Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Palpebral Fissure Distance Measurement</title>
          <description>Change from baseline in PFD by regimen against placebo and between regimen.&#xD;
The PFD is the distance from the upper lid margin to the lower lid margin measured through the central visual axis. It will be measured from the external photograph using handheld calipers and the millimeter ruler as the legend.</description>
          <population>Intent to Treat Population</population>
          <units>Millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0, Hour 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="1.16"/>
                    <measurement group_id="O2" value="6.5" spread="1.10"/>
                    <measurement group_id="O3" value="6.5" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 13, Hour 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="1.35"/>
                    <measurement group_id="O2" value="7.1" spread="1.72"/>
                    <measurement group_id="O3" value="6.6" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 13, Hour 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="1.51"/>
                    <measurement group_id="O2" value="7.5" spread="1.45"/>
                    <measurement group_id="O3" value="6.8" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contrast Sensitivity</title>
        <description>Change from baseline in CS by regimen against placebo and between regimen.&#xD;
The Pelli-Robson contrast sensitivity chart will be used at a distance of 1 meter. The subject was instructed to begin reading the letters at the top of the chart and to continue reading across and down the chart. Testing was discontinued when 2 of 3 letters were named incorrectly. The test was scored using the letter-by-letter method where a value of 0.05 log CS is given per correct letter (Haymes et al, 2006).</description>
        <time_frame>Baseline (Day 0, Hour 0), Visit 4 (Day 13, Hour 2) and Visit 4 (Day 13, Hour 6)</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>RVL-1201 Once Daily</title>
            <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
          </group>
          <group group_id="O2">
            <title>RVL-1201 Twice Daily</title>
            <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
          </group>
          <group group_id="O3">
            <title>RVL-1201 Vehicle (Placebo)</title>
            <description>RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201 Vehicle Placebo: RVL-1201 Vehicle Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Contrast Sensitivity</title>
          <description>Change from baseline in CS by regimen against placebo and between regimen.&#xD;
The Pelli-Robson contrast sensitivity chart will be used at a distance of 1 meter. The subject was instructed to begin reading the letters at the top of the chart and to continue reading across and down the chart. Testing was discontinued when 2 of 3 letters were named incorrectly. The test was scored using the letter-by-letter method where a value of 0.05 log CS is given per correct letter (Haymes et al, 2006).</description>
          <population>Intent to Treat Population</population>
          <units>Letters Read</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0, Hour 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" spread="4.05"/>
                    <measurement group_id="O2" value="34.7" spread="6.14"/>
                    <measurement group_id="O3" value="33.3" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 13, Hour 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" spread="4.45"/>
                    <measurement group_id="O2" value="35.8" spread="4.28"/>
                    <measurement group_id="O3" value="35.3" spread="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 13, Hour 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" spread="3.81"/>
                    <measurement group_id="O2" value="36.8" spread="3.29"/>
                    <measurement group_id="O3" value="35.1" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corrected Snellen Visual Acuity</title>
        <description>Change from baseline in VA by regimen against placebo and between regimen.&#xD;
Corrected Snellen VA measurement was performed with the Snellen eye chart using subjects current corrective lens prescription at a distance equivalent to 20 feet (6 meters).</description>
        <time_frame>Baseline (Day 0, Hour 0), Visit 4 (Day 13, Hour 2) and Visit 4 (Day 13, Hour 6)</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>RVL-1201 QD</title>
            <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
          </group>
          <group group_id="O2">
            <title>RVL-1201 BID</title>
            <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
          </group>
          <group group_id="O3">
            <title>RVL-1201 Vehicle (Placebo) BID</title>
            <description>RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201 Vehicle Placebo: RVL-1201 Vehicle Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Corrected Snellen Visual Acuity</title>
          <description>Change from baseline in VA by regimen against placebo and between regimen.&#xD;
Corrected Snellen VA measurement was performed with the Snellen eye chart using subjects current corrective lens prescription at a distance equivalent to 20 feet (6 meters).</description>
          <population>Intent to Treat Population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0, Hour 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.071" spread="0.0859"/>
                    <measurement group_id="O2" value="0.086" spread="0.0988"/>
                    <measurement group_id="O3" value="0.081" spread="0.0770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 13, Hour 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" spread="0.0739"/>
                    <measurement group_id="O2" value="0.024" spread="0.1043"/>
                    <measurement group_id="O3" value="0.059" spread="0.1190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 13, Hour 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" spread="0.0891"/>
                    <measurement group_id="O2" value="0.023" spread="0.0949"/>
                    <measurement group_id="O3" value="0.053" spread="0.1018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 Days</time_frame>
      <desc>AEs were those with onset after randomization or if occurring prior to randomization, that worsened after randomization.</desc>
      <group_list>
        <group group_id="E1">
          <title>RVL-1201 QD</title>
          <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
        </group>
        <group group_id="E2">
          <title>RVL-1201 BID</title>
          <description>RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201: RVL-1201 0.1% Ophthalmic Solution</description>
        </group>
        <group group_id="E3">
          <title>RVL-1201 Vehicle (Placebo) BID</title>
          <description>RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose&#xD;
RVL-1201 Vehicle Placebo: RVL-1201 Vehicle Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ocular Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation Site Dryness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Instillation Site Foreign Body Sensation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Instillation Site Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Instillation Site Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. Director, Clinical Development</name_or_title>
      <organization>RVL Pharmaceuticals</organization>
      <phone>908-809-1423</phone>
      <email>mvelasco@osmotica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

